CN101663308A - N-甲基色胺钙五水合物(dcp)和基于它的治疗方法 - Google Patents

N-甲基色胺钙五水合物(dcp)和基于它的治疗方法 Download PDF

Info

Publication number
CN101663308A
CN101663308A CN200780048992A CN200780048992A CN101663308A CN 101663308 A CN101663308 A CN 101663308A CN 200780048992 A CN200780048992 A CN 200780048992A CN 200780048992 A CN200780048992 A CN 200780048992A CN 101663308 A CN101663308 A CN 101663308A
Authority
CN
China
Prior art keywords
dcp
administering
patient
effective amount
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780048992A
Other languages
English (en)
Chinese (zh)
Inventor
P·莫赫诺
W·普夫莱德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SanRX Pharmaceuticals Inc
Original Assignee
SanRX Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SanRX Pharmaceuticals Inc filed Critical SanRX Pharmaceuticals Inc
Publication of CN101663308A publication Critical patent/CN101663308A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CN200780048992A 2006-10-30 2007-10-30 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法 Pending CN101663308A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86354706P 2006-10-30 2006-10-30
US60/863,547 2006-10-30

Publications (1)

Publication Number Publication Date
CN101663308A true CN101663308A (zh) 2010-03-03

Family

ID=39344907

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780048992A Pending CN101663308A (zh) 2006-10-30 2007-10-30 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法

Country Status (7)

Country Link
US (2) US7662820B2 (enExample)
EP (1) EP2094715B1 (enExample)
JP (1) JP2010508349A (enExample)
CN (1) CN101663308A (enExample)
CA (1) CA2668262A1 (enExample)
ES (1) ES2394227T3 (enExample)
WO (1) WO2008054793A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257589A1 (en) * 2002-08-22 2004-03-11 Sumitomo Pharmaceuticals Company, Limited Remedy for integration dysfunction syndrome
AU2004249621B2 (en) 2003-06-23 2009-08-06 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
WO2005080976A1 (ja) * 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
EP2502628B1 (en) 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
CN101663308A (zh) * 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
US20120251495A1 (en) * 2008-01-18 2012-10-04 Phillip Moheno Pterin based therapies for inflammatory conditions
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
WO2013116238A1 (en) * 2012-01-30 2013-08-08 Sanrx Pharmaceuticals, Inc. Calcium folate (cafolate) and therapeutic methods based thereon
CN104788300B (zh) * 2014-01-22 2017-01-11 南京华威医药科技开发有限公司 欧司哌米芬多晶型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358953B1 (en) * 1998-10-22 2002-03-19 Phillip B. B. Moheno Pterin antineoplastic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342797A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101663308A (zh) * 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358953B1 (en) * 1998-10-22 2002-03-19 Phillip B. B. Moheno Pterin antineoplastic agents

Also Published As

Publication number Publication date
US7662820B2 (en) 2010-02-16
US20080166355A1 (en) 2008-07-10
CA2668262A1 (en) 2008-05-08
WO2008054793A3 (en) 2008-08-28
EP2094715A2 (en) 2009-09-02
US20100105692A1 (en) 2010-04-29
JP2010508349A (ja) 2010-03-18
ES2394227T3 (es) 2013-01-23
WO2008054793A2 (en) 2008-05-08
EP2094715A4 (en) 2010-04-28
EP2094715B1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
CN101663308A (zh) N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
JP6312919B2 (ja) 細菌株を含む組成物
KR101633134B1 (ko) 시티딘 유사체의 경구 제형 및 그의 사용 방법
BR112020017090A2 (pt) Imunoterapias relacionadas com microbioma
JP6837700B2 (ja) ジピベフリンの使用方法
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
JPH0349893B2 (enExample)
CN102573826A (zh) 用于治疗癌症的喷他脒组合
CN102119214A (zh) 适合于癌症治疗的包含体外扩增的t淋巴细胞和血管形成抑制剂的组合物
WO2021012886A1 (zh) 一种抗肿瘤的联合用药物组合物及其应用
US20200237904A1 (en) Methods and Compositions Useful for Treating Cancer
JPWO2005094878A1 (ja) 抗腫瘍作用を有する組成物
JPH0617304B2 (ja) 制癌剤
CN116059167A (zh) 一种共载药胶束及其协同药物体系与制备方法和应用
TWI454280B (zh) Pharmaceutical composition or combination
EP2097085A2 (en) Therapeutic materials and methods
CN116350795B (zh) 一种线粒体靶向非诺贝特酸、构建方法及应用
HK1139952A (en) Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
CN104434948B (zh) 一种抗胰腺癌的药物组合物及其应用
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
JP7624241B2 (ja) がんの予防または治療用薬学的組成物
Zou et al. An Intermediate-crystalline Phase Manganese Nanoadjuvant Potently Activates cGAS-STING Signaling and Antitumor Immunity via Immunometabolism Normalization
EP4226939A1 (en) Novel use of mycobacterium tuberculosis extract
WO2023072968A1 (en) Compositions comprising bacterial strains
US8586561B2 (en) Anti-tumor agent comprising cytidine derivative and carboplatin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139952

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100303

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1139952

Country of ref document: HK